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Evidence Based Medicine
What are the emerging therapeutic alternatives to Warfarin in Stroke
patients? How would the results of RE-LY benefit Pakistanis?
Maria Khan,1 Emmon Raza,2 Ayeesha Kamran Kamal3
International Cerebrovascular Translational Clinical Research Training Program, Stroke Service,1 Medical College,2
Stroke Service and Vascular Fellowship Program,3 Aga Khan University Hospital, Karachi, Pakistan.

Randomized Evaluation of Long-Term
Anticoagulation (RE-LY)
Why is this study important and noteworthy?
Warfarin is currently the gold standard for stroke
prevention in patients with atrial fibrillation. Therapy with
Warfarin requires frequent International Normalized Ratio
(INR) monitoring due to its low therapeutic index.
Furthermore, multiple food and drug interactions lead to noncompliance and frequent dose adjustment.
Dabigatran, the active form of the prodrug Dabigatran
etexilate, is a competitive inhibitor of thrombin. This new
anticoagulant does not require frequent monitoring and had
been evaluated in a pilot trial with promising results.
RE-LY was a randomized study which tested two
fixed doses of Dabigatran (110 and 150 mg twice daily) given
in a blinded manner, with open label use of Warfarin in
patients with atrial fibrillation and an increased risk of stroke.

Who were the participants?
A total of 18,113 patients from 951 clinical centers
across 44 countries were recruited for this non-inferiority trial
and followed for a median duration of 2 years. There was a
fair representation from Asia, with patients being recruited
from India, China, Korea and Japan. All patients had
documented atrial fibrillation on electrocardiography at the
time of screening or within 6 months beforehand and, a risk
of stroke. 63.6% of the patients were men and the mean age
was 71 years.

What was the intervention?
Patients were assigned randomly to one of three
treatment groups. Two groups received either 110 mg or 150
mg twice daily dose of Dabigatran in a blinded fashion. The
third group received Warfarin in 1, 3 or 5 mg tablets adjusting
to an International Normalized Ratio (INR) of 2.0 to 3.0 in an
unblinded fashion. Concomitant use of Aspirin at a dose of
<100 mg per day or any other antiplatelet agent was
permitted. All three groups were comparable in terms of age,
gender, type of atrial fibrillation, co-morbidities and
CHADS2 scores.
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What was the outcome?
Primary outcome (stroke or systemic embolism) in the
110 mg Dabigatran group was 1.53% per year compared with
1.11% per year in 150 mg Dabigatran group and 1.69% per
year in the Warfarin group. This rendered both doses of
Dabigatran to be noninferior to Warfarin.
There were significantly fewer haemorrhagic strokes
in the Dabigatran arms at both doses compared to Warfarin
with RR of 0.31 with 110 mg and 0.26 with 150 mg (p<0.001
in both cases)dose. Rates of major bleeding were 3.36%,
2.71% and 3.11% per year for Warfarin, Dabigatran 110 mg
(relative risk 0.80, p=0.003) and Dabigatran 150 mg (relative
risk 0.93, p=0.31) respectively.
A subgroup analysis compared the two doses of
Dabigatran with Warfarin in secondary prevention of stroke
in a subset of patients with prior stroke or transient ischaemic
attack. They found a higher annual rate of stroke in this
subgroup. A significant reduction in all-cause mortality was
found with 110 mg Dabigatran but not 150 mg Dabigatran
compared with Warfarin in this subgroup. The 150 mg dose
of Dabigatran was superior to Warfarin for the primary
outcome in this subgroup analysis of patients with previous
stroke or transient ischaemic attack (RR reduction 25%).

What were the conclusions?
The authors concluded that both doses of Dabigatran were
noninferior to Warfarin. The 150 mg dose of Dabigatran was
superior to Warfarin as far as stroke or systemic embolism
prevention was concerned both in patients with or without prior
stroke or transient ischaemic attack. The 110 mg dose of Dabigatran
was superior to Warfarin with respect to major bleeding.

How does this impact our clinical practice?
There are considerable difficulties with the practical
administration of warfarin in Pakistan. Dabigatran may be a
welcome future alternative particularly in a population which
is already at a higher risk of haemorrhagic strokes compared
to the rest of the world.
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